SubHero Banner

Tagrisso® (osimertinib) – New indication

On December 18, 2020 - the FDA announced the approval of AstraZeneca’s Tagrisso (osimertinib), as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.

Download PDF